How New Biotech Companies Bring Antibody Treatments to Clinical Trials

​New biotech companies now drive a growing share of targeted cancer therapies entering clinical development. They play a central role in the antibody and antibody-drug conjugate (ADC) pipeline, with many programs in trials originating from smaller firms rather than pharmaceutical giants. This shift appears in the number of biotechs advancing monoclonal antibodies through clinical stages.

Antibody treatments rely on laboratory-made proteins that attach to specific markers on cancer cells (proteins that signal a cell’s identity). Some of these therapies, called antibody-drug conjugates, link the targeting precision of antibodies with potent cancer-killing drugs that release their payload at the tumor site. Unlike traditional chemotherapy, which affects both healthy and diseased cells, this approach targets clearly identified targets.

Smaller companies are increasingly shaping early antibody programs for clinical testing through formal agreements and regulatory strategies. They design development plans around clear licensing or partnership goals, aiming to advance assets to stages where larger firms can step in. This approach moves promising therapies forward without the resources of a major pharmaceutical company. Instead of tracing each discovery back to academic labs, today’s pathway revolves around how these firms prepare assets for licensing, financing, and regulatory clearance.

Securing legal rights comes first. Startups or small developers often sign exclusive licensing agreements with larger companies, transferring development rights for specific ADC programs. These agreements set responsibilities, timelines, and commercial terms, creating the legal structure that attracts private investment and supports development.

Once rights are in place, companies raise the capital needed for laboratory work, manufacturing, and regulatory preparation. Early-stage biotechs typically work with venture funds, specialized investors, or strategic partners to hit these milestones. Recent ADC sector deals reflect how partnerships and acquisitions are becoming increasingly crucial as assets advance.

Momentum around ADCs has triggered a surge of significant transactions involving small developers. For example, investors acquired ProfoundBio in a multibillion-dollar deal after the company hit key milestones. At the same time, other firms entered into exclusive licensing agreements with large pharmaceutical partners to expand their global reach. Large pharmaceutical companies increasingly view these deals as a way to secure promising ADC pipelines early rather than develop them in-house. These deals show how promising assets can rush from early development into major pipelines, sometimes before late-stage trials begin.

Before human testing begins, companies run preclinical programs to assess safety and manufacturing feasibility. At this stage, companies generate the data required for the Investigational New Drug (IND) application, including laboratory and animal studies, and produce clinical-grade batches under appropriate quality systems. FDA guidance outlines standards for Phase 1 investigational drugs and confirms that manufacturing controls apply even at this early point.

After regulators review preclinical data, therapies move into a staged clinical trial process. Phase I tests safety in a small patient group, Phase II examines effectiveness and dosing, and Phase III expands to larger populations to confirm results before regulatory review. The FDA defines these phases as part of the standard development sequence, ensuring each stage builds on the last.

Regulators influence how quickly programs advance. The FDA, for instance, temporarily placed a partial hold on a BioNTech-partnered ADC trial and later lifted it with new dosing conditions. This example shows how safety reviews can pause development and then allow testing to continue under defined parameters.

For many small biotech firms, partnerships or acquisitions become essential once early trials succeed. Larger pharmaceutical companies bring manufacturing scale, distribution networks, and regulatory depth. Recent licensing agreements and acquisitions in the ADC field demonstrate how these collaborations quicken development and extend patient access.

Jason Sheasby

Shop